Abhishek Maiti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abhishek Maiti has a total of 333 co-authors. Here are the top co-authors by number of shared publications:
- Naval Daver
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
45 shared publications - Hagop M. Kantarjian
Department of Leukemia The University of Texas, MD Anderson Cancer Center Houston Texas USA
43 shared publications - Courtney Denton Dinardo
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA
42 shared publications - Tapan Mahendra Kadia
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA
42 shared publications - Farhad Ravandi
The University of Texas MD Anderson Cancer Center
38 shared publications - Marina Konopleva
Albert Einstein College of Medicine
38 shared publications
Latest Publications
- 29 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (18) , 2278-2293
A dual MYC and GSPT1 protein degrader for MYC-driven hematologic malignancies
Direct targeting of the oncoprotein MYC has not yet been successful. Here we report a novel dual protein degrader, GT19630, which binds directly to MYC and G1 to S phase transition protein 1 (GSPT1). GT19630 disrupts a novel feedforward loop of MYC and GSPT1, in which MYC promotes transcription of GSPT1, and GSPT1 senses the stop codon of MYC to properly terminate its translation. The agent induces an integrated stress response and abrogates oxidative phosphorylation through inhibition of the tricarboxylic acid cycle, resulting in apoptosis. GT19630 has superior activity compared with GSPT1-targeting molecular glues. GT19630 induces profound antiproliferative effects and apoptosis at low nanomolar concentrations in a multitude of leukemia and lymphoma cell lines and primary samples, including those with TP53 mutations. GT19630 is highly active in vivo in models of therapy-resistant hematologic malignancies, including Burkitt lymphoma, acute myeloid leukemia (AML), and multiple myeloma. CD34+ AML blasts overexpress MYC protein compared with normal hematopoietic stem/progenitor cells (HSPCs), and GT19630 induces greater cytotoxicity in AML cells compared with normal HSPCs. Further, GT19630 restores sensitivity to venetoclax and profoundly prolongs survival in vivo in venetoclax-resistant AML. GT19630 was well tolerated in humanized Crbn mice. In conclusion, our data support the development of the MYC/GSPT1 degrader GT19630 as a therapeutic strategy for MYC-driven hematologic malignancies.
- 29 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (18) , 2278-2293
A dual MYC and GSPT1 protein degrader for MYC-driven hematologic malignancies
Direct targeting of the oncoprotein MYC has not yet been successful. Here we report a novel dual protein degrader, GT19630, which binds directly to MYC and G1 to S phase transition protein 1 (GSPT1). GT19630 disrupts a novel feedforward loop of MYC and GSPT1, in which MYC promotes transcription of GSPT1, and GSPT1 senses the stop codon of MYC to properly terminate its translation. The agent induces an integrated stress response and abrogates oxidative phosphorylation through inhibition of the tricarboxylic acid cycle, resulting in apoptosis. GT19630 has superior activity compared with GSPT1-targeting molecular glues. GT19630 induces profound antiproliferative effects and apoptosis at low nanomolar concentrations in a multitude of leukemia and lymphoma cell lines and primary samples, including those with TP53 mutations. GT19630 is highly active in vivo in models of therapy-resistant hematologic malignancies, including Burkitt lymphoma, acute myeloid leukemia (AML), and multiple myeloma. CD34+ AML blasts overexpress MYC protein compared with normal hematopoietic stem/progenitor cells (HSPCs), and GT19630 induces greater cytotoxicity in AML cells compared with normal HSPCs. Further, GT19630 restores sensitivity to venetoclax and profoundly prolongs survival in vivo in venetoclax-resistant AML. GT19630 was well tolerated in humanized Crbn mice. In conclusion, our data support the development of the MYC/GSPT1 degrader GT19630 as a therapeutic strategy for MYC-driven hematologic malignancies.
- Open Access
- 30 September 2026
- Published by Springer Nature in Blood Cancer Journal
High MECOM protein levels confer adverse prognosis in acute myeloid leukemia independent of Chromosome 3 abnormalities
- 30 September 2026
- Published by Springer Nature in Blood Cancer Journal
Open AccessHigh MECOM protein levels confer adverse prognosis in acute myeloid leukemia independent of Chromosome 3 abnormalities
- Open Access
- 8 September 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4) , 100300
Combination therapy with nelarabine, pegaspargase, and venetoclax for adult patients with R/R T-cell ALL/LBL
- 8 September 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4) , 100300
Open AccessCombination therapy with nelarabine, pegaspargase, and venetoclax for adult patients with R/R T-cell ALL/LBL
- Open Access
- 27 June 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia
Inotuzumab ozogamicin, an anti-CD22 antibody-drug conjugate, has demonstrated high response rates and measurable residual disease (MRD)-negativity in acute lymphoblastic leukemia (ALL). This phase 2 single-center study evaluated inotuzumab 0.6 mg/m2 day 1 and 0.3 mg/m2 day 8 (cycle 1) followed by 0.3 mg/m2 days 1 and 8 (cycles 2-6) for adults with B-cell ALL in morphologic remission with detectable MRD (≥1 × 10-4 by multiparameter flow cytometry, BCR::ABL1 transcripts ≥0.01% by polymerase chain reaction [PCR], or ≥1 × 10-6 by next-generation sequencing [NGS]). Thirty-seven patients (median age 49 years) were treated, including 17 with Philadelphia-chromosome (Ph)-negative ALL and 20 with Ph-positive ALL. Twenty-eight patients (76%) were in first remission (CR1). Overall, 26 patients (70%) achieved MRD-negativity, including 76% of patients with Ph-negative ALL and 65% of patients with Ph-positive ALL. The NGS MRD-negativity rate was 73%. With a median follow-up of 50 months, the median overall survival (OS) was 61 months, with a median relapse-free survival (RFS) of 40 months. Patients treated in CR1 vs CR2+ had a median OS that was not reached versus 14 months, respectively (p = 0.056). Three cases (8%) of non-fatal sinusoidal obstructive syndrome (SOS) were observed. Inotuzumab was safe and effective at eradicating MRD.
- 27 June 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessInotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia
Inotuzumab ozogamicin, an anti-CD22 antibody-drug conjugate, has demonstrated high response rates and measurable residual disease (MRD)-negativity in acute lymphoblastic leukemia (ALL). This phase 2 single-center study evaluated inotuzumab 0.6 mg/m2 day 1 and 0.3 mg/m2 day 8 (cycle 1) followed by 0.3 mg/m2 days 1 and 8 (cycles 2-6) for adults with B-cell ALL in morphologic remission with detectable MRD (≥1 × 10-4 by multiparameter flow cytometry, BCR::ABL1 transcripts ≥0.01% by polymerase chain reaction [PCR], or ≥1 × 10-6 by next-generation sequencing [NGS]). Thirty-seven patients (median age 49 years) were treated, including 17 with Philadelphia-chromosome (Ph)-negative ALL and 20 with Ph-positive ALL. Twenty-eight patients (76%) were in first remission (CR1). Overall, 26 patients (70%) achieved MRD-negativity, including 76% of patients with Ph-negative ALL and 65% of patients with Ph-positive ALL. The NGS MRD-negativity rate was 73%. With a median follow-up of 50 months, the median overall survival (OS) was 61 months, with a median relapse-free survival (RFS) of 40 months. Patients treated in CR1 vs CR2+ had a median OS that was not reached versus 14 months, respectively (p = 0.056). Three cases (8%) of non-fatal sinusoidal obstructive syndrome (SOS) were observed. Inotuzumab was safe and effective at eradicating MRD.
- 22 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (18) , 4188-4195
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia
Purpose: Outcomes in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) remain discouraging despite rapid expansion of treatment paradigms over the past decade. Clinicians must often decide between conventional salvage treatment regimens or enrollment on clinical trials. Experimental Design: We retrospectively identified 657 patients with AML in second treatment salvage and compared the outcomes of those who received investigational agents (N=354) versus conventional salvage regimens (N=303). Results: Conventional salvage was associated with higher response rates (CR/CRi rate: 22% vs 12%, P=0.0008) and higher early mortality rates (60-day mortality: 17% vs 7%, P=0.0002). There was no difference in rates of bridging to allogeneic stem cell transplant (7% vs 10%, P=0.2), event free survival (EFS; median: 1.5 months vs 2.0 months, P=0.9) or overall survival (OS; median: 4.1 months vs 4.5 months, P=0.8). A subgroup analysis of conventional regimens showed improved EFS (median EFS: 3.6 months vs 1.4 months, P=0.004) and a trend towards improved OS (median OS: 7.5 months vs 3.8 months, P=0.06) with the addition of venetoclax in venetoclax-naïve patients. Conclusion: Enrollment of R/R patients on clinical trials is a suitable alternative to conventional salvage regimens, offering novel therapeutic approaches to improve upon the historically dismal outcomes in this setting.
- 22 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (18) , 4188-4195
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia
Purpose: Outcomes in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) remain discouraging despite rapid expansion of treatment paradigms over the past decade. Clinicians must often decide between conventional salvage treatment regimens or enrollment on clinical trials. Experimental Design: We retrospectively identified 657 patients with AML in second treatment salvage and compared the outcomes of those who received investigational agents (N=354) versus conventional salvage regimens (N=303). Results: Conventional salvage was associated with higher response rates (CR/CRi rate: 22% vs 12%, P=0.0008) and higher early mortality rates (60-day mortality: 17% vs 7%, P=0.0002). There was no difference in rates of bridging to allogeneic stem cell transplant (7% vs 10%, P=0.2), event free survival (EFS; median: 1.5 months vs 2.0 months, P=0.9) or overall survival (OS; median: 4.1 months vs 4.5 months, P=0.8). A subgroup analysis of conventional regimens showed improved EFS (median EFS: 3.6 months vs 1.4 months, P=0.004) and a trend towards improved OS (median OS: 7.5 months vs 3.8 months, P=0.06) with the addition of venetoclax in venetoclax-naïve patients. Conclusion: Enrollment of R/R patients on clinical trials is a suitable alternative to conventional salvage regimens, offering novel therapeutic approaches to improve upon the historically dismal outcomes in this setting.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (2) , e2500170
Global Epidemiologic Trends of Early-Onset Cancers From 1990 to 2021 and Projection to 2040
PURPOSE: Early-onset cancer (EOC), defined as cancer occurring in individuals age 15-49 years, represents a growing global health burden. This study aims to assess the epidemiologic trends of EOC from 1990 to 2021 and project future incidence and mortality trends up to 2040. MATERIALS AND METHODS: Using data from the Global Burden of Disease (GBD) 2021 study, we analyzed the age-specific incidence rate (AsIR) and death rate (AsDR) per 100,000 patient-years for 31 cancer types across 204 countries. Statistical modeling, including the two sample t test, was done to estimate the standard deviations among each group, which is plugged in the denominator to compute the statistic. Autoregressive integrated moving average and exponential smoothing state space were employed for forecasting future trends. RESULTS: In 2021, there were approximately 23.6 million new EOC cases and 0.99 million deaths globally. The highest AsIRs were observed in breast, nonmelanoma skin, and cervical cancers, with the highest AsDRs seen in breast and lung cancers in 2021. Although AsIR has increased globally, AsDR has declined from 1990 to 2021. EOC disproportionately affected women, particularly in high-income countries. Risk factor analysis highlights obesity, tobacco use, and dietary patterns as key contributors to EOC burden. Projected analysis till 2040 revealed relatively stable AsIR and declining AsDR for overall EOCs. CONCLUSION: The increasing global burden of EOC underscores the need for targeted strategies. Regional disparities highlight the importance of health care access in mitigating EOC mortality. Healthy lifestyle could reduce the burden of EOC.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (2) , e2500170
Global Epidemiologic Trends of Early-Onset Cancers From 1990 to 2021 and Projection to 2040
PURPOSE: Early-onset cancer (EOC), defined as cancer occurring in individuals age 15-49 years, represents a growing global health burden. This study aims to assess the epidemiologic trends of EOC from 1990 to 2021 and project future incidence and mortality trends up to 2040. MATERIALS AND METHODS: Using data from the Global Burden of Disease (GBD) 2021 study, we analyzed the age-specific incidence rate (AsIR) and death rate (AsDR) per 100,000 patient-years for 31 cancer types across 204 countries. Statistical modeling, including the two sample t test, was done to estimate the standard deviations among each group, which is plugged in the denominator to compute the statistic. Autoregressive integrated moving average and exponential smoothing state space were employed for forecasting future trends. RESULTS: In 2021, there were approximately 23.6 million new EOC cases and 0.99 million deaths globally. The highest AsIRs were observed in breast, nonmelanoma skin, and cervical cancers, with the highest AsDRs seen in breast and lung cancers in 2021. Although AsIR has increased globally, AsDR has declined from 1990 to 2021. EOC disproportionately affected women, particularly in high-income countries. Risk factor analysis highlights obesity, tobacco use, and dietary patterns as key contributors to EOC burden. Projected analysis till 2040 revealed relatively stable AsIR and declining AsDR for overall EOCs. CONCLUSION: The increasing global burden of EOC underscores the need for targeted strategies. Regional disparities highlight the importance of health care access in mitigating EOC mortality. Healthy lifestyle could reduce the burden of EOC.
- 28 August 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (11) , 2118-2122
Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies
- 28 August 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (11) , 2118-2122
Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies
- Top Cited Papers
- 20 August 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (24) , 2692-2699
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML
PURPOSE: The development of targeted therapeutics has revolutionized treatment for elderly patients with AML. Two doublet regimens are approved in the frontline setting for intensive chemotherapy (IC)–ineligible AML: venetoclax (VEN) in combination with hypomethylating agent (HMA) therapy and azacitidine (AZA) plus ivosidenib (IVO) specifically for IDH1 -mutated AML. Although both regimens have improved AML outcomes, most patients will either not respond to frontline therapy or relapse, with dismal salvage outcomes. METHODS: We herein report on 60 newly diagnosed IC-ineligible patients treated at our institution with triplet regimens for isocitrate dehydrogenase ( IDH )–mutant AML. Patients received either AZA + VEN + IVO on NCT03471260 ( IDH1 -mutated patients only) or oral decitabine + VEN + IVO/enasidenib on NCT04774393 (arms for IDH1- and IDH2 -mutant disease, respectively). RESULTS: The triplet regimens were well tolerated with low early mortality (n = 1 [2%] in 60 days) and a similar safety profile to HMA + VEN and isocitrate dehydrogenase inhibitor doublet regimens. The composite complete remission rate (CRc) was 92% (55/60), with an overall response rate of 95% (57/60). With a median follow-up of 27.4 months, the median overall survival (OS) has not yet been reached. The 2-year OS was 69% with a 2-year cumulative incidence of relapse of 24%. Patients with treated-secondary AML (tsAML) experienced inferior outcomes with a CRc of 71% (12/17) and a 2-year OS of 34%; the 2-year OS was 84% in patients without tsAML. Nineteen patients (32%) transitioned to stem cell transplant, and 51% remain on study. CONCLUSION: Given the excellent outcomes of IDH-triplet therapy for newly diagnosed, IC-ineligible IDH -mutant AML, further prospective studies comparing IDH-triplet versus IDH-doublet regimens are warranted.
- 20 August 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (24) , 2692-2699
Top Cited PapersOutcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML
PURPOSE: The development of targeted therapeutics has revolutionized treatment for elderly patients with AML. Two doublet regimens are approved in the frontline setting for intensive chemotherapy (IC)–ineligible AML: venetoclax (VEN) in combination with hypomethylating agent (HMA) therapy and azacitidine (AZA) plus ivosidenib (IVO) specifically for IDH1 -mutated AML. Although both regimens have improved AML outcomes, most patients will either not respond to frontline therapy or relapse, with dismal salvage outcomes. METHODS: We herein report on 60 newly diagnosed IC-ineligible patients treated at our institution with triplet regimens for isocitrate dehydrogenase ( IDH )–mutant AML. Patients received either AZA + VEN + IVO on NCT03471260 ( IDH1 -mutated patients only) or oral decitabine + VEN + IVO/enasidenib on NCT04774393 (arms for IDH1- and IDH2 -mutant disease, respectively). RESULTS: The triplet regimens were well tolerated with low early mortality (n = 1 [2%] in 60 days) and a similar safety profile to HMA + VEN and isocitrate dehydrogenase inhibitor doublet regimens. The composite complete remission rate (CRc) was 92% (55/60), with an overall response rate of 95% (57/60). With a median follow-up of 27.4 months, the median overall survival (OS) has not yet been reached. The 2-year OS was 69% with a 2-year cumulative incidence of relapse of 24%. Patients with treated-secondary AML (tsAML) experienced inferior outcomes with a CRc of 71% (12/17) and a 2-year OS of 34%; the 2-year OS was 84% in patients without tsAML. Nineteen patients (32%) transitioned to stem cell transplant, and 51% remain on study. CONCLUSION: Given the excellent outcomes of IDH-triplet therapy for newly diagnosed, IC-ineligible IDH -mutant AML, further prospective studies comparing IDH-triplet versus IDH-doublet regimens are warranted.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Representativeness of study participants
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Representativeness of study participants